Will natural products remain an important source of drug research for the future?
Authors:
- Louis J NisbetLNLouis J Nisbet
- Michael MooreMMMichael Moore
- 1 December 1997
- journal article
- review article
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 8 (6) , 708-712
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: New antirejection drugsExpert Opinion on Therapeutic Patents, 1996
- Syntheses and Structure−Activity Relationships of the Second-Generation Antitumor Taxoids: Exceptional Activity against Drug-Resistant Cancer CellsJournal of Medicinal Chemistry, 1996
- Chapter 34. To Market, To Market - 19951996
- Docetaxel < Prop INN; USAN >Drugs of the Future, 1995
- Identification and characterization of a novel diketopiperazine as a modulator of P-glycoprotein-mediated multidrug resistanceAnti-Cancer Drugs, 1994
- Comparison of Topoisomerase I Inhibition, DNA Damage, and Cytotoxicity of Camptothecin Derivatives Presently in Clinical TrialsJNCI: Journal of the National Cancer Institute, 1994
- Marine animal and terrestrial plant anticancer constituentsPure and Applied Chemistry, 1994
- Chapter 34. To Market, To Market - 19931994
- The Current Status of Camptothecin Analogues as Antitumor AgentsJNCI: Journal of the National Cancer Institute, 1993
- Chapter 32. Taxol: From Discovery to Therapeutic Use1993